CY1116575T1 - Χρησεις αρωματικου-κατιοντικου πεπτιδιου - Google Patents
Χρησεις αρωματικου-κατιοντικου πεπτιδιουInfo
- Publication number
- CY1116575T1 CY1116575T1 CY20151100675T CY151100675T CY1116575T1 CY 1116575 T1 CY1116575 T1 CY 1116575T1 CY 20151100675 T CY20151100675 T CY 20151100675T CY 151100675 T CY151100675 T CY 151100675T CY 1116575 T1 CY1116575 T1 CY 1116575T1
- Authority
- CY
- Cyprus
- Prior art keywords
- aromatic
- net positive
- cationic peptide
- minimum
- relationship
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
Abstract
Η εφεύρεση παρέχει μέθοδο ελάττωσης ή πρόληψης της μετάπτωσης μιτοχονδριακής διαπερατότητας. Η μέθοδος περιλαμβάνει τη χορήγηση αποτελεσματικής ποσότητας αρωματικού-κατιοντικού πεπτιδίου που έχει ένα τουλάχιστον καθαρό θετικό φορτίο, ένα ελάχιστο 4 αμινοξέων, ένα μέγιστο περίπου 20 αμινοξέων, μια σχέση μεταξύ του ελάχιστου αριθμού καθαρών θετικών φορτία (pm) και του συνολικού αριθμού υπολειμμάτων αμινοξέων (r) όπου 3pm είναι ο μεγαλύτερος αριθμός ο οποίος είναι μικρότερος ή ίσος με r + 1, και a η σχέση μεταξύ του ελάχιστου αριθμού αρωματικών ομάδων (a) και του συνολικού αριθμού καθαρών θετικών φορτίων (pt) όπου 2a είναι ο μεγαλύτερος αριθμός ο οποίος είναι μικρότερος ή ίσος με pt + 1, εκτός όταν το a είναι 1, το pt μπορεί επίσης να είναι 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44477703P | 2003-02-04 | 2003-02-04 | |
US53569004P | 2004-01-08 | 2004-01-08 | |
EP20130178043 EP2656854B1 (en) | 2003-02-04 | 2004-02-03 | Uses of aromatic-cationic peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116575T1 true CY1116575T1 (el) | 2017-03-15 |
Family
ID=32853391
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100064T CY1114959T1 (el) | 2003-02-04 | 2014-01-24 | Μεθοδοι προληψης της μεταπτωσης μιτοχονδριακης διαπερατοτητας |
CY20151100675T CY1116575T1 (el) | 2003-02-04 | 2015-08-03 | Χρησεις αρωματικου-κατιοντικου πεπτιδιου |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100064T CY1114959T1 (el) | 2003-02-04 | 2014-01-24 | Μεθοδοι προληψης της μεταπτωσης μιτοχονδριακης διαπερατοτητας |
Country Status (14)
Country | Link |
---|---|
US (8) | US7576061B2 (el) |
EP (9) | EP3659618A1 (el) |
JP (7) | JP4838114B2 (el) |
CN (3) | CN102784383B (el) |
AU (1) | AU2004209663B2 (el) |
CA (1) | CA2515080C (el) |
CY (2) | CY1114959T1 (el) |
DK (3) | DK2865385T3 (el) |
ES (3) | ES2540897T3 (el) |
HK (6) | HK1131995A1 (el) |
HU (1) | HUE027110T2 (el) |
PT (2) | PT1599216E (el) |
SI (1) | SI2656854T1 (el) |
WO (1) | WO2004070054A2 (el) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3659618A1 (en) | 2003-02-04 | 2020-06-03 | Cornell Research Foundation, Inc. | Uses of aromatic-cationic peptide |
PT2604285E (pt) * | 2003-05-01 | 2014-11-12 | Cornell Res Foundation Inc | Método e complexos transportadores para entregar moléculas às células |
CA2971928C (en) * | 2004-01-23 | 2019-01-08 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
EP3725324A1 (en) * | 2005-09-16 | 2020-10-21 | Cornell Research Foundation, Inc. | Aromatic-cationic peptide for use in a method for reducing cd36 expression |
AU2014203126B2 (en) * | 2005-09-16 | 2016-03-10 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
ES2458870T3 (es) | 2008-02-07 | 2014-05-07 | Cornell University | Procedimientos para prevenir o tratar la resistencia a la insulina |
DK2262520T3 (en) | 2008-02-26 | 2017-08-07 | Univ Cornell | COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury |
DE102008061044A1 (de) | 2008-12-11 | 2010-06-17 | Henkel Ag & Co. Kgaa | Zusammensetzung mit antioxidativ wirksamen Peptiden |
EP3199173B1 (en) * | 2009-03-20 | 2019-04-24 | The General Hospital Corporation d/b/a Massachusetts General Hospital | D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention and treatment of burn injuries |
US20110039766A1 (en) * | 2009-08-12 | 2011-02-17 | Szeto Hazel H | Methods for preventing or treating metabolic syndrome |
DK2470191T3 (da) | 2009-08-24 | 2014-07-07 | Stealth Peptides Int Inc | Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande |
CN102711785A (zh) * | 2009-10-05 | 2012-10-03 | 康奈尔大学 | 预防或治疗心力衰竭的方法 |
EP2519249A4 (en) * | 2009-12-31 | 2013-06-26 | Stealth Peptides Int Inc | METHODS OF REALIZING AORTO-CORONARY BRIDGE |
US20130195837A1 (en) * | 2009-12-31 | 2013-08-01 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
CA2787331A1 (en) * | 2010-01-25 | 2011-07-28 | Hazel H. Szeto | Aromatic-cationic peptides and uses of same |
EP3167896A1 (en) * | 2010-02-26 | 2017-05-17 | University of Florida Research Foundation, Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
EP3560508A1 (en) * | 2010-03-15 | 2019-10-30 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
US20110245183A1 (en) | 2010-04-06 | 2011-10-06 | Perricone Nicholas V | Topical Uses of Szeto-Schiller Peptides |
US20110245182A1 (en) | 2010-04-06 | 2011-10-06 | Perricone Nicholas V | Topical Uses of Szeto-Schiller Peptides |
EP2942354A1 (en) * | 2010-05-03 | 2015-11-11 | Stealth Peptides International, Inc. | Aromatic-Cationic Peptides and Uses of Same |
WO2014137496A1 (en) * | 2013-03-08 | 2014-09-12 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
US20160176930A1 (en) | 2010-07-09 | 2016-06-23 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
CN106620645A (zh) * | 2010-07-09 | 2017-05-10 | 康德生物医疗技术公司 | 预防或治疗缺血/再灌注损伤之后无复流的方法 |
US20120083452A1 (en) | 2010-09-30 | 2012-04-05 | Perricone Nicholas V | Topical Anesthetic Uses of Szeto-Schiller Peptides |
CN107219358A (zh) * | 2011-03-24 | 2017-09-29 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
CA2849073A1 (en) * | 2011-09-19 | 2013-03-28 | Gencia Corporation | Modified creatine compounds |
CN106913860A (zh) * | 2011-09-29 | 2017-07-04 | 梅约医学教育与研究基金会 | 芳族阳离子肽和使用它们的方法 |
EP2768516A4 (en) * | 2011-10-17 | 2015-08-19 | Univ Cornell | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF |
EP3656394A1 (en) * | 2011-12-09 | 2020-05-27 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
DK2830644T3 (en) | 2012-03-30 | 2017-02-27 | Stealth Peptides Int Inc | Methods and Preparations for the Prevention and Treatment of Neuropathy |
EP3132800A1 (en) * | 2012-08-02 | 2017-02-22 | Stealth Peptides International, Inc. | Methods for treatment of atherosclerosis |
KR20160009008A (ko) * | 2012-10-22 | 2016-01-25 | 스텔스 바이오테라퓨틱스 코포레이션 | 심부전과 관련된 위험 및 이와 관련된 인자를 감소시키는 방법 |
CN115990242A (zh) | 2013-03-01 | 2023-04-21 | 康德生物医疗有限公司 | 预防或治疗巴斯综合征的方法和组合物 |
US10793597B2 (en) * | 2013-03-01 | 2020-10-06 | Stealth Biotherapeutics Corp | Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation |
EP2989120A4 (en) | 2013-04-25 | 2017-04-19 | Carmel-Haifa University Economic Corp. | Synthetic anti-inflammatory peptides and use thereof |
WO2014209905A2 (en) | 2013-06-26 | 2014-12-31 | Stealth Peptides International, Inc. | Methods and compositions for detecting and diagnosing diseases and conditions |
WO2015017781A1 (en) * | 2013-08-01 | 2015-02-05 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating leber's hereditary optic neuropathy |
CA2920020C (en) | 2013-08-02 | 2023-03-14 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention and treatment of friedreich's ataxia |
CA2925757A1 (en) * | 2013-09-30 | 2015-04-02 | Cornell University | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
EP3154694A1 (en) | 2014-06-13 | 2017-04-19 | Children's Medical Center Corporation | Products and methods to isolate mitochondria |
PL3160984T3 (pl) | 2014-06-25 | 2021-10-25 | Flamma S.P.A. | Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylol- fenyloalaninoamidu |
WO2016001042A1 (en) | 2014-06-30 | 2016-01-07 | Flamma S.P.A. | Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide |
WO2016004093A2 (en) * | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
CN104306954B (zh) * | 2014-09-25 | 2016-08-24 | 中山大学 | Wry三肽在制备治疗阿尔茨海默症药物中的用途 |
US10603325B2 (en) | 2014-10-29 | 2020-03-31 | University Of Maryland | Methods of treating age-related symptoms in mammals and compositions therefor |
WO2017015660A1 (en) * | 2015-07-23 | 2017-01-26 | Salk Institute For Biological Studies | Prevention and treatment of aging and neurodegenerative diseases |
US20200308220A1 (en) * | 2015-11-30 | 2020-10-01 | Peter Schiller | Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome |
CN115160402A (zh) * | 2016-03-11 | 2022-10-11 | 隐形生物治疗公司 | 结晶盐形式 |
CN109563131A (zh) | 2016-04-11 | 2019-04-02 | 卡诺有限责任公司 | 手性肽 |
WO2018100893A1 (ja) | 2016-11-30 | 2018-06-07 | 株式会社ダイセル | 撮像装置用レンズモジュール及びその製造方法 |
US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
EP3668837B1 (en) | 2017-08-17 | 2022-07-06 | XWPharma Ltd. | Preparation and uses of reactive oxygen species scavenger derivatives |
ES2947741T3 (es) | 2017-09-04 | 2023-08-17 | Xwpharma Ltd | Preparación y uso de un barredor de especies reactivas de oxígeno |
JP6958860B2 (ja) * | 2017-11-07 | 2021-11-02 | 学校法人自治医科大学 | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 |
US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
IL284006B1 (en) * | 2018-12-18 | 2024-08-01 | Stealth Biotherapeutics Corp | Mitochondria-targeted peptides |
WO2020222866A1 (en) * | 2019-05-02 | 2020-11-05 | Children's Medical Center Corporation | Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents |
EP3771467A1 (en) | 2019-07-30 | 2021-02-03 | Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau | Ss-31 for the prevention and/or treatment of aneurysm |
CN116390723A (zh) | 2020-09-09 | 2023-07-04 | 社会利益网络公司 | 用于将生物素递送至线粒体的方法和组合物 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5602100A (en) | 1988-06-30 | 1997-02-11 | Astra Ab | Dermorphin analogs having pharmacological activity |
DE68926269T2 (de) | 1988-06-30 | 1996-08-14 | Astra Ab | Dermorphin-Analoge, deren Herstellungsverfahren, pharmazeutische Zusammensetzungen und Methode zur therapeutischen Behandlung unter Verwendung der Analoge |
US5652122A (en) | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
ATE165208T1 (de) * | 1990-01-17 | 1998-05-15 | Univ California | Zusammensetzung zur verbesserung der lebenserhaltung biologischer materialien |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
IS4261A (is) | 1994-02-21 | 1995-08-22 | Astra Aktiebolag | Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra |
ATE255450T1 (de) * | 1995-06-09 | 2003-12-15 | Hisamitsu Pharmaceutical Co | Matrix für iontophorese |
US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
CA2270661A1 (en) * | 1996-10-07 | 1998-04-16 | Lawrence Joseph Heinz | Novel compounds useful as neuro-protective agents |
US5885958A (en) | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
WO1999029721A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
CA2329709A1 (en) * | 1998-04-24 | 1999-11-04 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
GB9905503D0 (en) * | 1999-03-10 | 1999-05-05 | Adprotech Plc | Novel compound formulations and methods of delivery |
SE9900961D0 (sv) | 1999-03-16 | 1999-03-16 | Astra Ab | Novel compounds |
WO2001025486A1 (en) * | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying rna binding compounds |
US6759520B1 (en) * | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
US20050192215A1 (en) | 2000-01-21 | 2005-09-01 | Malabika Ghosh | Methods and materials relating to novel polypeptides and polynucleotides |
US7498297B2 (en) * | 2000-07-18 | 2009-03-03 | Cornell Research Foundation | Medicinal uses of mu-opioid receptor agonists |
US6900178B2 (en) | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
JP2004523490A (ja) * | 2000-11-28 | 2004-08-05 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | 二置換カルボサイクリックサイクロフィリン結合化合物とその用途 |
US6545097B2 (en) * | 2000-12-12 | 2003-04-08 | Scimed Life Systems, Inc. | Drug delivery compositions and medical devices containing block copolymer |
WO2002059080A2 (en) * | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
US20030077826A1 (en) * | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
ATE434418T1 (de) * | 2001-02-16 | 2009-07-15 | Cordis Corp | Verfahren zur herstellung eines ballonkatheter- stentapplikationssystems mit furchen |
WO2002074194A2 (en) * | 2001-03-16 | 2002-09-26 | Sts Biopolymers, Inc. | Stent with medicated multi-layer hydrid polymer coating |
JPWO2002102833A1 (ja) * | 2001-06-15 | 2004-09-30 | 千寿製薬株式会社 | 新規エンドモルフィン誘導体 |
CN101440124B (zh) * | 2003-02-04 | 2012-07-18 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
EP3659618A1 (en) * | 2003-02-04 | 2020-06-03 | Cornell Research Foundation, Inc. | Uses of aromatic-cationic peptide |
PT2604285E (pt) | 2003-05-01 | 2014-11-12 | Cornell Res Foundation Inc | Método e complexos transportadores para entregar moléculas às células |
JP2005005762A (ja) * | 2003-06-09 | 2005-01-06 | Fujitsu Ltd | 送信電力制御方法及び装置 |
US7232824B2 (en) | 2003-09-30 | 2007-06-19 | Scios, Inc. | Quinazoline derivatives as medicaments |
CA2971928C (en) | 2004-01-23 | 2019-01-08 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
EP3725324A1 (en) | 2005-09-16 | 2020-10-21 | Cornell Research Foundation, Inc. | Aromatic-cationic peptide for use in a method for reducing cd36 expression |
-
2004
- 2004-02-03 EP EP19207802.0A patent/EP3659618A1/en not_active Withdrawn
- 2004-02-03 DK DK14186875.2T patent/DK2865385T3/en active
- 2004-02-03 EP EP18199147.2A patent/EP3479838A1/en not_active Withdrawn
- 2004-02-03 DK DK04707809.2T patent/DK1599216T3/da active
- 2004-02-03 EP EP20210900.5A patent/EP3842055A1/en active Pending
- 2004-02-03 EP EP20130178043 patent/EP2656854B1/en not_active Expired - Lifetime
- 2004-02-03 EP EP11009660.9A patent/EP2491943B1/en not_active Expired - Lifetime
- 2004-02-03 PT PT47078092T patent/PT1599216E/pt unknown
- 2004-02-03 HU HUE13178043A patent/HUE027110T2/en unknown
- 2004-02-03 SI SI200432258T patent/SI2656854T1/sl unknown
- 2004-02-03 ES ES13178043.9T patent/ES2540897T3/es not_active Expired - Lifetime
- 2004-02-03 WO PCT/US2004/003193 patent/WO2004070054A2/en active Application Filing
- 2004-02-03 CN CN201210177633.0A patent/CN102784383B/zh not_active Expired - Lifetime
- 2004-02-03 EP EP14186875.2A patent/EP2865385B1/en not_active Expired - Lifetime
- 2004-02-03 PT PT131780439T patent/PT2656854E/pt unknown
- 2004-02-03 AU AU2004209663A patent/AU2004209663B2/en not_active Expired
- 2004-02-03 CA CA2515080A patent/CA2515080C/en not_active Expired - Lifetime
- 2004-02-03 ES ES14186875.2T patent/ES2605504T3/es not_active Expired - Lifetime
- 2004-02-03 DK DK13178043.9T patent/DK2656854T3/en active
- 2004-02-03 EP EP04707809.2A patent/EP1599216B9/en not_active Expired - Lifetime
- 2004-02-03 JP JP2006503317A patent/JP4838114B2/ja not_active Expired - Lifetime
- 2004-02-03 CN CN2012100218642A patent/CN102617706A/zh active Pending
- 2004-02-03 EP EP17192437.6A patent/EP3305313A1/en not_active Withdrawn
- 2004-02-03 CN CN201410412683.1A patent/CN104225574B/zh not_active Expired - Lifetime
- 2004-02-03 US US10/771,232 patent/US7576061B2/en active Active
- 2004-02-03 ES ES04707809T patent/ES2436011T3/es not_active Expired - Lifetime
- 2004-02-03 EP EP16192437.8A patent/EP3144009A1/en not_active Withdrawn
-
2006
- 2006-06-30 US US11/427,804 patent/US7718620B2/en active Active
- 2006-11-03 HK HK09110947.4A patent/HK1131995A1/xx not_active IP Right Cessation
- 2006-11-03 HK HK06112161.2A patent/HK1090571A1/xx not_active IP Right Cessation
-
2010
- 2010-04-02 US US12/753,403 patent/US20100190718A1/en not_active Abandoned
- 2010-10-28 JP JP2010241738A patent/JP5775285B2/ja not_active Expired - Lifetime
-
2011
- 2011-09-28 US US13/247,648 patent/US8404646B2/en not_active Expired - Lifetime
-
2013
- 2013-02-27 US US13/778,994 patent/US8957030B2/en not_active Expired - Lifetime
- 2013-05-17 HK HK13105866.5A patent/HK1178794A1/xx not_active IP Right Cessation
- 2013-09-03 JP JP2013182343A patent/JP5837542B2/ja not_active Expired - Lifetime
-
2014
- 2014-01-24 CY CY20141100064T patent/CY1114959T1/el unknown
- 2014-04-30 HK HK14104163.7A patent/HK1190930A1/xx not_active IP Right Cessation
- 2014-10-01 JP JP2014202889A patent/JP6126059B2/ja not_active Expired - Lifetime
-
2015
- 2015-01-13 US US14/595,946 patent/US20150359838A1/en not_active Abandoned
- 2015-06-23 HK HK15105970.6A patent/HK1204999A1/xx not_active IP Right Cessation
- 2015-07-06 JP JP2015135207A patent/JP6166312B2/ja not_active Expired - Lifetime
- 2015-08-03 CY CY20151100675T patent/CY1116575T1/el unknown
- 2015-10-28 HK HK15110675.4A patent/HK1209652A1/xx not_active IP Right Cessation
-
2017
- 2017-02-15 JP JP2017025764A patent/JP2017095519A/ja active Pending
-
2019
- 2019-01-08 JP JP2019001256A patent/JP2019089773A/ja active Pending
- 2019-09-12 US US16/569,573 patent/US20200038472A1/en not_active Abandoned
-
2022
- 2022-02-10 US US17/668,744 patent/US20230293624A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116575T1 (el) | Χρησεις αρωματικου-κατιοντικου πεπτιδιου | |
CY1115305T1 (el) | Μεθοδοι για την προληψη ή τη θεραπεια της αντιστασης στην ινσουλινη | |
CY1109439T1 (el) | Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους | |
CY1110177T1 (el) | Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης | |
CY1115885T1 (el) | Αντιστρεπτα πεγκυλιωμενα (pegylated) φαρμακα | |
CY1115580T1 (el) | Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης | |
DE60325968D1 (de) | Prodrugs von exzitatorischen aminosäuren | |
CY1113243T1 (el) | Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4 | |
CY1112330T1 (el) | Πρωτεϊνες συνδεσης gag | |
BR0205491B1 (pt) | compressor com elemento espiralado e com injeção de vapor. | |
WO2007035640A3 (en) | Methods for reducing cd36 expression | |
BR0209434A (pt) | Peptìdeos antimicrobianos e composições | |
CY1108570T1 (el) | Gd3-μιμητικα πεπτιδια | |
RU2009147217A (ru) | Новые противоопухолевые соединения | |
ES2171923T3 (es) | Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos. | |
ATE278710T1 (de) | Antimikrobiell wirksame peptide | |
CY1112236T1 (el) | Πεπτιδια που ειναι σε θεση να αναστελλουν την αλληλεπιδραση μεταξυ των πρεσενιλινων και του βητα-αμυλοειδους πεπτιδιου ή του προδρομου | |
EA200000950A1 (ru) | Ингерентно свето- и термостабилизированные полиамиды с улучшенной устойчивостью к мокрым обработкам | |
ATE495247T1 (de) | Chromoprotein und fluoroproteine | |
ITRM940134A1 (it) | Circuito per combinare insieme gruppi di sequenze di cifre per formare codici di identificazione telefonici e relativo procedimento | |
DE69800172D1 (de) | Mit Organohydrogensiloxan-Vernetzen härtbare Organosiloxan-Zusammensetzunt mit verbesserten Hysterese-Eigenschaften | |
DE69532302D1 (de) | Peptide gegen pilzen | |
DE60304067D1 (de) | Kraftstoffeinspritzsystem | |
KR910018404A (ko) | 혈소판-응집 억제제 | |
NO20051840L (no) | IHNV G-protein til immunstimulering. |